Resolution of cardiac surgical bleeding with the combination of 4-factor prothrombin complex concentrate and fresh frozen plasma following lack of response to fresh frozen plasma alone in a patient with severe factor XI deficiency.
Percy Boateng, Mala Varma, Lilyanne Chen, Hein Kyaw, Nay Lin Kyaw, Joseph Yoe
{"title":"Resolution of cardiac surgical bleeding with the combination of 4-factor prothrombin complex concentrate and fresh frozen plasma following lack of response to fresh frozen plasma alone in a patient with severe factor XI deficiency.","authors":"Percy Boateng, Mala Varma, Lilyanne Chen, Hein Kyaw, Nay Lin Kyaw, Joseph Yoe","doi":"10.1097/MBC.0000000000001236","DOIUrl":null,"url":null,"abstract":"<p><p>Factor XI deficiency is associated with a bleeding tendency in some patients. Factor XI helps to reduce fibrinolysis. Bleeding risk is increased in factor XI-deficient patients during surgeries with high fibrinolytic activity, including nasopharyngeal/oropharyngeal and genitourinary surgeries. Treatment options for factor XI-deficient patients include fresh frozen plasma (FFP), antifibrinolytics, recombinant factor VIIa, and factor XI concentrates (available in Australia, Canada, and some European countries). 4-factor prothrombin complex concentrate (4-factor PCC) is an extract of FFP comprised of unactivated factors II, VII, IX, and X, proteins C and S, and heparin. It has been used for cardiac surgical bleeding. We report the first case of a patient with severe factor XI deficiency and cardiac surgical bleeding, which resolved with the combination of 4-factor PCC and FFP after lack of response to FFP alone.</p>","PeriodicalId":8992,"journal":{"name":"Blood Coagulation & Fibrinolysis","volume":null,"pages":null},"PeriodicalIF":1.2000,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Blood Coagulation & Fibrinolysis","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/MBC.0000000000001236","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/6/21 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Factor XI deficiency is associated with a bleeding tendency in some patients. Factor XI helps to reduce fibrinolysis. Bleeding risk is increased in factor XI-deficient patients during surgeries with high fibrinolytic activity, including nasopharyngeal/oropharyngeal and genitourinary surgeries. Treatment options for factor XI-deficient patients include fresh frozen plasma (FFP), antifibrinolytics, recombinant factor VIIa, and factor XI concentrates (available in Australia, Canada, and some European countries). 4-factor prothrombin complex concentrate (4-factor PCC) is an extract of FFP comprised of unactivated factors II, VII, IX, and X, proteins C and S, and heparin. It has been used for cardiac surgical bleeding. We report the first case of a patient with severe factor XI deficiency and cardiac surgical bleeding, which resolved with the combination of 4-factor PCC and FFP after lack of response to FFP alone.
一名严重因子 XI 缺乏症患者在单用新鲜冰冻血浆无效后,联合使用 4 因子凝血酶原复合物浓缩物和新鲜冰冻血浆,解决了心脏手术出血问题。
因子 XI 缺乏症与某些患者的出血倾向有关。因子 XI 有助于减少纤维蛋白溶解。因子 XI 缺乏症患者在进行高纤维蛋白溶解活性手术(包括鼻咽/咽喉和泌尿生殖系统手术)时,出血风险会增加。因子 XI 缺乏症患者的治疗方案包括新鲜冰冻血浆(FFP)、抗纤维蛋白溶解剂、重组因子 VIIa 和因子 XI 浓缩物(在澳大利亚、加拿大和一些欧洲国家有售)。4 因子凝血酶原复合物浓缩物(4 因子 PCC)是一种由未活化的因子 II、VII、IX 和 X、蛋白质 C 和 S 以及肝素组成的 FFP 提取物。它已被用于心脏手术出血。我们报告了第一例严重因子 XI 缺乏和心脏手术出血的患者,该患者在单用 FFP 无效后,联合使用了 4 因子 PCC 和 FFP。
期刊介绍:
Blood Coagulation & Fibrinolysis is an international fully refereed journal that features review and original research articles on all clinical, laboratory and experimental aspects of haemostasis and thrombosis. The journal is devoted to publishing significant developments worldwide in the field of blood coagulation, fibrinolysis, thrombosis, platelets and the kininogen-kinin system, as well as dealing with those aspects of blood rheology relevant to haemostasis and the effects of drugs on haemostatic components